VEC.L - Vectura Group plc

LSE - LSE Delayed Price. Currency in GBp
85.00
+0.55 (+0.65%)
At close: 4:35PM BST
Stock chart is not supported by your current browser
Previous Close84.45
Open84.80
Bid62.00 x 382500
Ask110.00 x 252100
Day's Range84.30 - 86.55
52 Week Range68.00 - 127.20
Volume2,147,215
Avg. Volume6,565,022
Market Cap563.138M
Beta0.45
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • High Growth Stocks To Invest In
    Simply Wall St.4 days ago

    High Growth Stocks To Invest In

    Old Mutual and Frenkel Topping Group are a few noticeable companies with a strong future outlook. The market’s optimistic sentiment towards these stocks indicates a level of confidence in theRead More...

  • Top Insider-Bought Stocks This Month
    Simply Wall St.last month

    Top Insider-Bought Stocks This Month

    Insiders ramping up their own shareholdings in their company sends a bullish signal about its future prospects. These insiders have unique insights into the underlying business, so they are well-placedRead More...

  • Top High Growth Stocks This Week
    Simply Wall St.2 months ago

    Top High Growth Stocks This Week

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VEC.L earnings conference call or presentation 21-Mar-18 9:30am GMT

    Full Year 2017 Vectura Group PLC Earnings Call

  • Zacks Small Cap Research2 months ago

    PULM: 2017 Financial Results; Business Update for 2018

    By Anita Dushyanth, PhD NASDAQ:PULM Financial Update: On March 13, 2018 Pulmatrix (NASDAQ:PULM) reported financial results for fiscal 2017. Cystic Fibrosis Foundation Therapeutics (CFFT) is a nonprofit ...

  • Reuters2 months ago

    Vectura posts wider 2017 loss, revenue rise

    The company, which bought rival SkyePharma for 441 million pounds in June 2016, said pretax loss stood at 102.2 million pounds against analysts' expectations of a loss of 88.7 million pounds, according to Thomson Reuters data. The asthma inhaler-maker said total royalties fell to 52.6 million pounds from 74.5 million pounds a year earlier. The company derives 35 percent of its revenue from royalties.

  • Reuters3 months ago

    GSK wins new reprieve as Hikma's generic Advair delayed again

    The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.

  • Reuters4 months ago

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".

  • PULM: Business And Financial Update For Third Quarter 2017
    Zacks Small Cap Research6 months ago

    PULM: Business And Financial Update For Third Quarter 2017

    On November 9, 2017 Pulmatrix (PULM) announced their third quarter financial results and provided operational highlights. As a reminder, the global ABPA-asthma market is a multi-billion dollar opportunity with the U.S. representing close to two-thirds (~60%) of this industry.  Management expects the Phase I studies supporting the PUR1900 program in both CF and severe asthma patients to create partnership opportunities for both indications.

  • Reuters7 months ago

    Hikma, Vectura in dispute with FDA over generic Advair

    LONDON (Reuters) - Hikma (HIK.L) and its partner Vectura (VEC.L) are in dispute with the Food and Drug Administration over their plans to launch a generic copy of GlaxoSmithKline's (GSK.L) popular lung ...

  • Does Zero-Debt Make Vectura Group plc (LSE:VEC) A Financially Strong Company?
    Simply Wall St.7 months ago

    Does Zero-Debt Make Vectura Group plc (LSE:VEC) A Financially Strong Company?

    Zero-debt allows substantial financial flexibility, especially for small-cap companies like Vectura Group plc (LSE:VEC), as the company does not have to adhere to strict debt covenants. However, it also facesRead More...

  • Thomson Reuters StreetEvents9 months ago

    Edited Transcript of VEC.L earnings conference call or presentation 6-Sep-17 8:30am GMT

    Q2 2017 Vectura Group PLC Earnings Call

  • Benzinga9 months ago

    Vectura Announces Major New Tiotropium Bromide PI Development Programme Accelerated Through Licensing of Pulmatrix Technology

    Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading device and formulation business for inhaled airways products, today announces it is progressing the development ...